SPAC Overview
Timeline Progress
About
Helix Acquisition Corp. II is a blank-check company seeking an unidentified business combination, with a stated focus on healthcare and related industries and a primary focus on biotechnology. It aims to provide a target with public-market access and draws on Cormorant's healthcare investment experience.
Investment Focus
Healthcare, Biopharmaceuticals
The terms and the filing trail behind Helix Acquisition Corp. II
What the sponsor registered, what the deal actually priced at, and every 8-K that moved it — unit structure, sponsor promote, and the dated lifecycle events, each linked to its filing.
- Unit structure as registered and as priced — price, warrant coverage, rights, trust per unit
- Sponsor promote: founder shares and percentage, private-placement warrants, trust deposit
- The full 8-K lifecycle timeline, each event linked to its filing
- Price history across the unit, share and warrant tickers
- Follow it, and see it change on your watchlist
SPAC Team
Sponsors
Leadership
Underwriters
Extended Team Information
Led by Bihua Chen, founder and managing member of Cormorant and former CEO and chair of Helix I; Caleb Tripp and Nebojsa Obradovic bring finance and legal/compliance experience at Cormorant; director nominees Mark McKenna and John Schmid have biopharmaceutical leadership and board experience.